- Home
- PROK vs BNTC Comparison
PROK vs BNTC Comparison
Compare PROK & BNTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PROK | BNTC |
|---|---|---|
| Founded | 2015 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 359.4M | 313.9M |
| IPO Year | 2021 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PROK | BNTC |
|---|---|---|
| Price | $1.68 | $9.12 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | $6.25 | ★ $24.33 |
| AVG Volume (30 Days) | ★ 1.4M | 190.1K |
| Earning Date | 11-09-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 6.67 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $893,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $7.83 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 1075.00 | N/A |
| 52 Week Low | $1.30 | $8.52 |
| 52 Week High | $3.48 | $16.76 |
Technical Indicators
Market Signals| Indicator | PROK | BNTC |
|---|---|---|
| Relative Strength Index (RSI) | 49.14 | 33.96 |
| Support Level | $1.55 | $8.89 |
| Resistance Level | $1.76 | $13.49 |
| Average True Range (ATR) | 0.10 | 0.76 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 48.39 | 20.00 |
Price Performance
Historical ComparisonAbout PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About BNTC Benitec Biopharma Inc.
Benitec Biopharma Inc is a clinical-stage biotechnology company focused on advancing novel genetic medicines. Its technology could provide a one-shot cure for a wide range of diseases that require strict, ongoing treatment regimens or have no effective treatment or only palliative care options. The Company is developing a silence-and-replace-based therapeutic (BB-301) for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD), a chronic, life-threatening genetic disorder. The company has a single operating segment, which is the business of discovery and development of therapeutic agents for the treatment of genetic disorders.